Y-mAbs has a powerful set of capabilities for the development of biologics. Our product development team includes some of the most talented and experienced professionals in the antibody industry.
Y-mAbs’ laboratories are located in Nutley, NJ at the former site of the Roche Institute of Molecular Biology is a state-of-the art facility for the development of novel antibody-based therapeutic and diagnostic agents for pediatric and adult cancers of high unmet medical need. Antibody discovery is accomplished through selection from fully human antibody phage display libraries or hybridoma methods, which is then followed by advanced protein engineering for optimal affinity, function, stability, manufacturability, and reduced risk of immunogenicity.
Y-mAbs’ protein engineering approach incorporates a core strategy. We rely on a rational design approach, in which scientists use their detailed knowledge of the structure and function of proteins to make desired changes. We combine this rational design strategy with advanced display and selection technologies to develop powerful therapeutic and diagnostic products. In partnership with MSK, we have developed advanced antibody platform technologies that have significantly higher therapeutic indices than conventional IgG antibodies.
Our company has the capability to support all clinical and regulatory activities from early stage development through license application submission, product approval and beyond. Y-mAbs is leading the clinical development of our product candidates targeting GD2 and B7-H3 originating from and created by MSK. We are currently supporting a series of active clinical programs. These programs range from Phase I to pivotal Phase II trials and require routine regulatory interactions.